Miura, J., Salama, A. K. S., Xu, X., Beasley, G. M., Al-Rohil, R., Brody, R., … Mitchell, T. C. (2025). 1604MO Randomization to adjuvant nivolumab or ipilimumab + nivolumab based on pathological response to a single dose of neoadjuvant nivolumab in stage III melanoma. In Annals of Oncology (Vol. 36, pp. S949–S949). Elsevier BV. https://doi.org/10.1016/j.annonc.2025.08.2232

Miura, J., A. K. S. Salama, X. Xu, G. M. Beasley, R. Al-Rohil, R. Brody, S. Mitnick, et al. “1604MO Randomization to adjuvant nivolumab or ipilimumab + nivolumab based on pathological response to a single dose of neoadjuvant nivolumab in stage III melanoma.” In Annals of Oncology, 36:S949–S949. Elsevier BV, 2025. https://doi.org/10.1016/j.annonc.2025.08.2232.

Miura J, Salama AKS, Xu X, Beasley GM, Al-Rohil R, Brody R, et al. 1604MO Randomization to adjuvant nivolumab or ipilimumab + nivolumab based on pathological response to a single dose of neoadjuvant nivolumab in stage III melanoma. In: Annals of Oncology. Elsevier BV; 2025. p. S949–S949.

Miura, J., et al. “1604MO Randomization to adjuvant nivolumab or ipilimumab + nivolumab based on pathological response to a single dose of neoadjuvant nivolumab in stage III melanoma.” Annals of Oncology, vol. 36, Elsevier BV, 2025, pp. S949–S949. Crossref, doi:10.1016/j.annonc.2025.08.2232.

Miura J, Salama AKS, Xu X, Beasley GM, Al-Rohil R, Brody R, Mitnick S, Tabita-Martinez J, Giles L, McGettigan S, Kreider K, Nandi A, Wang G, Mo G, Schuchter L, Amaravadi R, Huang A, Gimotty P, Karakousis G, Mitchell TC. 1604MO Randomization to adjuvant nivolumab or ipilimumab + nivolumab based on pathological response to a single dose of neoadjuvant nivolumab in stage III melanoma. Annals of Oncology. Elsevier BV; 2025. p. S949–S949.